XML 52 R38.htm IDEA: XBRL DOCUMENT v3.2.0.727
Research and License Agreements - Additional Information (Detail) - USD ($)
 1 Months Ended 6 Months Ended 18 Months Ended
Jun. 30, 2015
Feb. 28, 2015
May. 31, 2014
Oct. 31, 2011
Jun. 30, 2015
Mar. 31, 2013
Dec. 31, 2014
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Accrued license and milestone fees $ 2,000,000       $ 2,000,000   $ 1,500,000
Accrued liability Paid for Research Agreement   $ 1,500,000          
Pfizer License Agreement [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Potential milestone payments upon the achievement of specified development milestones       $ 115,000,000      
Potential milestone payments upon the achievement of specified regulatory milestones       70,000,000      
Potential milestone payments upon the achievement specified levels of annual net sales of licensed products       135,000,000      
Payment made on execution of milestone agreement       $ 22,500,000      
Period of up-front payment         1 year 6 months    
Revenue 20,000,000   $ 15,000,000   $ 20,000,000    
Percentage of obligations payable for all future milestone and royalty payments received with respect to rivipansel         10.00%    
Accrued license and milestone fees 2,000,000       $ 2,000,000   $ 1,500,000
Non-refundable payment against milestone payment $ 20,000,000   $ 15,000,000   $ 20,000,000    
Pfizer License Agreement [Member] | Up-Front Payment Arrangement [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Amount received and recognized as revenue           $ 22,500,000